Literature DB >> 6282375

Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors.

N J Cusack, S M Hourani.   

Abstract

1 Adenosine 5'-diphosphate (ADP) induces human platelet aggregation and noncompetitively inhibits stimulated human platelet adenylate cyclase; it has been suggested that these two effects are mediated by separate ADP receptors on the platelet surface. 2 Adenosine 5'-triphosphate and seven adenine nucleotide analogues were tested as inhibitors of both effects of ADP on human platelets, and were found to be competitive. 3 pA2 values were calculated for each antagonist for inhibition of both effects of ADP, and a good correlation (correlation coefficient 0.87; p less than 0.01) was found between the pA2 values for inhibition of ADP-induced aggregation and the pA2 values for inhibition of the effect of ADP on stimulated adenylate cyclase. 4 Such a correlation does not support the suggestion that ADP-induced aggregation and the inhibition by ADP of stimulated adenylate cyclase are mediated by two separate receptors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282375      PMCID: PMC2068757          DOI: 10.1111/j.1476-5381.1982.tb09210.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  ADP-induced refractory state of platelets in vitro. I. Methodological studies on aggregation in platelet rich plasma.

Authors:  S Holme; H Holmsen
Journal:  Scand J Haematol       Date:  1975-09

2.  Synthesis and properties of diastereoisomers of adenosine 5'-(O-1-thiotriphosphate) and adenosine 5'-(O-2-thiotriphosphate).

Authors:  F Eckstein; R S Goody
Journal:  Biochemistry       Date:  1976-04-20       Impact factor: 3.162

3.  Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.

Authors:  R J Haslam; G M Rosson
Journal:  Mol Pharmacol       Date:  1975-09       Impact factor: 4.436

4.  The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation.

Authors:  D E Macfarlane; D C Mills
Journal:  Blood       Date:  1975-09       Impact factor: 22.113

5.  Binding of adenosine diphosphate to human blood platelets and to isolated blood platelet membranes.

Authors:  J P Lips; J J Sixma; M E Schiphorst
Journal:  Biochim Biophys Acta       Date:  1980-04-03

6.  Absolute configuration of the diastereomers of adenosine 5'-O-(1-thiotriphosphate): consequences for the stereochemistry of polymerization by DNA-dependent RNA polymerase from Escherichia coli.

Authors:  P M Burgers; F Eckstein
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

7.  Effect of the rapid shape change of platelets on the transmission and scattering of light through plasma.

Authors:  F Michal; G V Born
Journal:  Nat New Biol       Date:  1971-06-16

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5'-monophosphate and adenosine 5'-triphosphate of human platelet aggregation induced by adenosine 5'-diphosphate.

Authors:  N J Cusack; S M Hourani
Journal:  Br J Pharmacol       Date:  1982-02       Impact factor: 8.739

10.  Effects of RP and SP diastereoisomers of adenosine 5'-O-(1-thiodiphosphate) on human platelets.

Authors:  N J Cusack; S M Hourani
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

View more
  16 in total

1.  Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.

Authors:  H S Park; S M Hourani
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Inhibition of human platelet adenylate cyclase by collagen fibres. Effect of collagen is additive with that of adrenaline, but interactive with that of thrombin.

Authors:  R W Farndale; A B Winkler; B R Martin; M J Barnes
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

3.  Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.

Authors:  S M Hourani; D A Hall; C J Nieman
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

Review 4.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

5.  Effects of alpha 2-adrenoceptor agonists and of related compounds on aggregation of, and on adenylate cyclase activity in, human platelets.

Authors:  K A Clare; M C Scrutton; N T Thompson
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

6.  FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.

Authors:  R G Humphries; W Tomlinson; A H Ingall; P A Cage; P Leff
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 7.  Nomenclature and classification of purinoceptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; J W Daly; T K Harden; K A Jacobson; P Leff; M Williams
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

8.  Ap4A and ADP-beta-S binding to P2 purinoceptors present on rat brain synaptic terminals.

Authors:  J Pintor; M A Díaz-Rey; M T Miras-Portugal
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

9.  Effects of analogues of adenine nucleotides on increases in intracellular calcium mediated by P2T-purinoceptors on human blood platelets.

Authors:  D A Hall; S M Hourani
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

10.  Effects of phosphorothioate analogues of ATP, ADP and AMP on guinea-pig taenia coli and urinary bladder.

Authors:  G Burnstock; N J Cusack; L A Meldrum
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.